Kesimpta is a medication used to treat relapsing forms of multiple sclerosis (MS) and clinically isolated syndrome (CIS). Kesimpta comes as a solution inside single-dose prefilled injection pens or ...

B-cell therapy for multiple sclerosis (MS) was first approved in 2017, after the anti-CD20 agent ocrelizumab (Ocrevus) demonstrated its ability to strongly suppress the acute inflammatory activity and ...

A study found brain atrophy progresses more slowly with age in RRMS, highlighting the need to factor age into MS clinical ...

During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained ...

In stable MS patients, stopping Ocrevus does not seem to increase the risk of disease activity or disability progression for ...

Ocrevus (ocrelizumab) is a long-term treatment for certain forms of multiple sclerosis and clinically isolated syndrome. Some people can safely take the drug for more than 10 years. Certain factors ...

As recently as the ‘90s, when patients arrived with all the typical symptoms — memory loss, double vision, fatigue — neurologists often avoided confirming what they most suspected: that the patient ...

In a significant advance for multiple sclerosis (MS) research, a new study has uncovered a potential link between certain initial symptoms and long-term disability outcomes. The research, published in ...

New research presented today at ECTRIMS 2024 reveals that initiating monoclonal antibody therapy during childhood, rather than delaying treatment until early adulthood, significantly reduces long-term ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...